Log in

NASDAQ:GRFSGRIFOLS S A/S Stock Price, Forecast & News

-0.77 (-3.83 %)
(As of 05/27/2020 04:00 PM ET)
Today's Range
Now: $19.34
50-Day Range
MA: $20.16
52-Week Range
Now: $19.34
Volume787,133 shs
Average Volume1.03 million shs
Market Capitalization$13.29 billion
P/E Ratio17.26
Dividend Yield1.69%
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.1Dividend Strength: 3.3Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.79 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:GRFS



Sales & Book Value

Annual Sales$5.71 billion
Cash Flow$1.56 per share
Book Value$11.56 per share


Net Income$700.16 million


Market Cap$13.29 billion
Next Earnings Date7/29/2020 (Estimated)

Receive GRFS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.

GRIFOLS S A/S (NASDAQ:GRFS) Frequently Asked Questions

How has GRIFOLS S A/S's stock been impacted by COVID-19 (Coronavirus)?

GRIFOLS S A/S's stock was trading at $20.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GRFS shares have decreased by 5.0% and is now trading at $19.3350. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of GRIFOLS S A/S?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GRIFOLS S A/S.

When is GRIFOLS S A/S's next earnings date?

GRIFOLS S A/S is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for GRIFOLS S A/S.

How were GRIFOLS S A/S's earnings last quarter?

GRIFOLS S A/S (NASDAQ:GRFS) issued its quarterly earnings data on Tuesday, April, 21st. The biotechnology company reported $0.25 EPS for the quarter, topping the Zacks' consensus estimate of $0.24 by $0.01. The biotechnology company had revenue of $1.43 billion for the quarter, compared to analysts' expectations of $1.40 billion. GRIFOLS S A/S had a return on equity of 11.92% and a net margin of 13.31%. View GRIFOLS S A/S's earnings history.

How often does GRIFOLS S A/S pay dividends? What is the dividend yield for GRIFOLS S A/S?

GRIFOLS S A/S declared a semi-annual dividend on Thursday, October 31st. Shareholders of record on Tuesday, December 3rd will be given a dividend of $0.169 per share on Wednesday, December 11th. This represents a dividend yield of 1.3%. The ex-dividend date is Monday, December 2nd. This is an increase from GRIFOLS S A/S's previous semi-annual dividend of $0.15. View GRIFOLS S A/S's dividend history.

When did GRIFOLS S A/S's stock split? How did GRIFOLS S A/S's stock split work?

GRIFOLS S A/S shares split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were payable to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

What price target have analysts set for GRFS?

7 Wall Street analysts have issued 12-month price objectives for GRIFOLS S A/S's shares. Their forecasts range from $22.50 to $22.50. On average, they expect GRIFOLS S A/S's share price to reach $22.50 in the next year. This suggests a possible upside of 16.4% from the stock's current price. View analysts' price targets for GRIFOLS S A/S.

Has GRIFOLS S A/S been receiving favorable news coverage?

Press coverage about GRFS stock has trended positive on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GRIFOLS S A/S earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutGRIFOLS S A/S.

Are investors shorting GRIFOLS S A/S?

GRIFOLS S A/S saw a increase in short interest in April. As of April 30th, there was short interest totaling 1,960,000 shares, an increase of 27.3% from the April 15th total of 1,540,000 shares. Based on an average daily trading volume, of 1,160,000 shares, the short-interest ratio is presently 1.7 days. Approximately 0.8% of the shares of the stock are sold short. View GRIFOLS S A/S's Current Options Chain.

Who are some of GRIFOLS S A/S's key competitors?

What other stocks do shareholders of GRIFOLS S A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GRIFOLS S A/S investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Abbott Laboratories (ABT), Alibaba Group (BABA), Pfizer (PFE), AbbVie (ABBV), Allergan (AGN), Nektar Therapeutics (NKTR) and Johnson & Johnson (JNJ).

Who are GRIFOLS S A/S's key executives?

GRIFOLS S A/S's management team includes the following people:
  • Mr. Raimon Grifols Roura, Co-CEO & Exec. Director (Age 55)
  • Mr. Tomás Dagá Gelabert, Vice Sec. & External Director (Age 63)
  • Mr. Víctor Grífols Deu, Co-CEO & Exec. Director (Age 42)
  • Mr. Alfredo Arroyo Guerra, CFO & Corp. VP (Age 61)
  • Mrs. Eva Bastida Tubau, Corp. VP and Director of Scientific & Medical Affairs

What is GRIFOLS S A/S's stock symbol?

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

Who are GRIFOLS S A/S's major shareholders?

GRIFOLS S A/S's stock is owned by a number of institutional and retail investors. Top institutional shareholders include AKO Capital LLP (1.93%), Pictet Asset Management Ltd. (1.14%), TPG Group Holdings SBS Advisors Inc. (0.67%), Capital Research Global Investors (0.63%), Janus Henderson Group PLC (0.59%) and Baillie Gifford & Co. (0.46%).

Which major investors are selling GRIFOLS S A/S stock?

GRFS stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., UBS Group AG, Morgan Stanley, Morgan Stanley, Two Sigma Investments LP, Bank of New York Mellon Corp, Deutsche Bank AG, and Van ECK Associates Corp.

Which major investors are buying GRIFOLS S A/S stock?

GRFS stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., TPG Group Holdings SBS Advisors Inc., Janus Henderson Group PLC, Impax Asset Management Group plc, AKO Capital LLP, Pelham Capital Ltd., Whitebox Advisors LLC, and Soros Fund Management LLC.

How do I buy shares of GRIFOLS S A/S?

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GRIFOLS S A/S's stock price today?

One share of GRFS stock can currently be purchased for approximately $19.34.

How big of a company is GRIFOLS S A/S?

GRIFOLS S A/S has a market capitalization of $13.29 billion and generates $5.71 billion in revenue each year. The biotechnology company earns $700.16 million in net income (profit) each year or $1.17 on an earnings per share basis. GRIFOLS S A/S employs 22,244 workers across the globe.

What is GRIFOLS S A/S's official website?

The official website for GRIFOLS S A/S is www.grifols.com.

How can I contact GRIFOLS S A/S?

GRIFOLS S A/S's mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 34-93-571-0000 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.